We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Two differing doses of deupirfenidone were assessed ...
Toby Maher, MD, PhD, professor of clinical medicine, Keck Medicine of USC, discusses the impact of changes in lung function in patients with idiopathic pulmonary fibrosis (IPF). How does the rate of ...
Please provide your email address to receive an email when new articles are posted on . The most impaired lung function trajectories included rapid decline. Researchers found a link between rapidly ...
Figure 2. Proportion of Patients with FVC Change from Baseline of Bexotegrast 320 mg Over 12 and 24 Weeks versus Placebo - Intent to Treat Population SOUTH SAN FRANCISCO, Calif., April 30, 2023 (GLOBE ...
Patients with SARD-ILD-PPF who continued nintedanib for 12 months or longer had better outcomes than those who discontinued therapy.
SAN FRANCISCO — The investigational oral agent nerandomilast was superior to placebo at slowing the decline in forced vital capacity (FVC) among patients with progressive pulmonary fibrosis (PF), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback